Low Libido while on Test Enanthate

[crabbypaddy]

I was looking for some advice; I am currently on my fist cycle in my 3rd week:

Test E 500 mg/week
D-Bol 30 mg/day
Tamoxifen 10 mg/day
Vitamin B-6/ 200mg/day

Good diet and working out have seen good results, feeling great!

Then last week I noticed a change in my libido, I was able to get an erection but diminished quickly, too quickly to get the job done. I went from total porn star to having problems getting hard. I don’t have to tell you I am a little nervous, I didn’t expect this effect until after my cycle. Any suggestions would be appreciated.

[Merc..]

Could be prolactin ......

AAS lower t-3 which , in turn , increase prolactin .. which can cause lower sex drive ....

Is this your first cycle ?? What's your stats ????


Merc.

[mx3]

could be estrogen related ditch the tamox for a while and see if that helps. I normally dont see a rise in libido on test e till about wks 4-6 so you may see a jump soon. also are you gyno prone cause if your not dont run the tamox till pct unless you see signs of gyno.

[mx3]

Could be prolactin ......

AAS lower t-3 which , in turn , increase prolactin .. which can cause lower sex drive ....

Is this your first cycle ?? What's your stats ????


Merc.

you beat me to it.

[Merc..]

you beat me to it.

LOL..

Yea, could be estrogen related also ... Too high or too low of estrogen levels can cause lowered sex drive ..


Merc.

[crabbypaddy]

This is my first cycle, and I have had no symptoms of gyno.
I’m sorry if this seems ignorant, but what stats do you need.
I am 37, male, 235lb, 20& bf aprox. BP is 140/90 workout every second day
2800 cal/day

[Merc..]

Yea stats are age , height , weight ....

like said it could be prolactin or estrogen causing it ..

[Merc..]

Do you have sex drive or is it that you cant get a hard on ??

[crabbypaddy]

I also have access to cytomel, maybe this would help with my T-3.

I might not have been totally clear as well, my desire is good, my wife is a kitten, but its just not as hard and without constant concentration, it all falls down.

[Merc..]

I also have access to cytomel, maybe this would help with my T-3.

I might not have been totally clear as well, my desire is good, my wife is a kitten, but its just not as hard and without constant concentration, it all falls down.

You could possibly look into something like Calais or some sorta ED med then ....



Merc.

[crabbypaddy]

I have never had any problems like this in the past, however this is my first time using AAS and I guess this could be a side effect?

Thanks Merc. / Mx3 I appreciate the help.

[spywizard]

Could be prolactin ......

AAS lower t-3 which , in turn , increase prolactin .. which can cause lower sex drive ....

Is this your first cycle ?? What's your stats ????


Merc.

yep, that's me on test after 3 weeks, the effects become very intolerable.

[Merc..]

yep, that's me on test after 3 weeks, the effects become very intolerable.

What up Spy ....

You ever tried using caber while doing a test cycle to see if it helped???



Merc.

[spywizard]

What up Spy ....

You ever tried using caber while doing a test cycle to see if it helped???



Merc.

I have, I have some in the frig right now.. love the stuff, but i don't like adding more and more chemicals, i'm starting to become a minimalist..

But yes, the caber works great..

[Merc..]

I have, I have some in the frig right now.. love the stuff, but i don't like adding more and more chemicals, i'm starting to become a minimalist..

But yes, the caber works great..

Yep , see it all the time .... people using meds unessarily ....

[perfectbeast2001]

Could be prolactin ......

AAS lower t-3 which , in turn , increase prolactin .. which can cause lower sex drive ....

Is this your first cycle ?? What's your stats ????


Merc.

would a supplemental dose of t3 help then?

[Merc..]

would a supplemental dose of t3 help then?

What up PB !!!!


Yea, t-3 could help ... But I think caber ( from what I have seen ) works better for this ...


Merc.

[Wavelover]

This is my first cycle, and I have had no symptoms of gyno.
I’m sorry if this seems ignorant, but what stats do you need.
I am 37, male, 235lb, 20& bf aprox. BP is 140/90 workout every second day
2800 cal/day

If you had ideal BP before using AAS, 140/90 considered high, then attributed by 20% bf could be the culprits for your ED.

Wavelover.

[inkslinger]

what is caber ?

[crabbypaddy]

I have some cytomel maybe I could use this to increase my t-3...

Could I have the full name for caber so I can read-up on it.

Your right spy, this is situation is becomming intolerable.

[Merc..]

Cabergoline

Generic Name: Cabergoline
Dosage Form: Tablets



Cabergoline Description
Cabergoline tablets contain Cabergoline, a dopamine receptor agonist. The chemical name for Cabergoline is 1-[(6-allylergolin-8β-yl)-carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea. Its empirical formula is C26H37N5O2, and its molecular weight is 451.62. The structural formula is as follows:




Cabergoline is a white powder soluble in ethyl alcohol, chloroform, and N, N-dimethylformamide (DMF); slightly soluble in 0.1N hydrochloric acid; very slightly soluble in n-hexane; and insoluble in water.

Cabergoline tablets, for oral administration, contain 0.5 mg of Cabergoline. Inactive ingredients consist of leucine, USP, and lactose, NF.


Cabergoline - Clinical Pharmacology

Mechanism of Action
The secretion of prolactin by the anterior pituitary is mainly under hypothalamic inhibitory control, likely exerted through release of dopamine by tuberoinfundibular neurons. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitro studies demonstrate that Cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. Cabergoline decreased serum prolactin levels in reserpinized rats. Receptor-binding studies indicate that Cabergoline has low affinity for dopamine D1, α1- and α2-adrenergic, and 5-HT1- and 5-HT2-serotonin receptors.


Clinical Studies
The prolactin-lowering efficacy of Cabergoline was demonstrated in hyperprolactinemic women in two randomized, double-blind, comparative studies, one with placebo and the other with bromocriptine. In the placebo-controlled study (placebo n=20; Cabergoline n=168), Cabergoline produced a dose-related decrease in serum prolactin levels with prolactin normalized after 4 weeks of treatment in 29%, 76%, 74% and 95% of the patients receiving 0.125, 0.5, 0.75, and 1.0 mg twice weekly respectively.

In the 8-week, double-blind period of the comparative trial with bromocriptine (Cabergoline n=223; bromocriptine n=236 in the intent-to-treat analysis), prolactin was normalized in 77% of the patients treated with Cabergoline at 0.5 mg twice weekly compared with 59% of those treated with bromocriptine at 2.5 mg twice daily. Restoration of menses occurred in 77% of the women treated with Cabergoline, compared with 70% of those treated with bromocriptine. Among patients with galactorrhea, this symptom disappeared in 73% of those treated with Cabergoline compared with 56% of those treated with bromocriptine.


Pharmacokinetics

Absorption
Following single oral doses of 0.5 mg to 1.5 mg given to 12 healthy adult volunteers, mean peak plasma levels of 30 to 70 picograms (pg)/mL of Cabergoline were observed within 2 to 3 hours. Over the 0.5-to-7 mg dose range, Cabergoline plasma levels appeared to be dose-proportional in 12 healthy adult volunteers and nine adult parkinsonian patients. A repeat-dose study in 12 healthy volunteers suggests that steady-state levels following a once-weekly dosing schedule are expected to be twofold to threefold higher than after a single dose. The absolute bioavailability of Cabergoline is unknown. A significant fraction of the administered dose undergoes a first-pass effect. The elimination half-life of Cabergoline estimated from urinary data of 12 healthy subjects ranged between 63 to 69 hours. The prolonged prolactin-lowering effect of Cabergoline may be related to its slow elimination and long half-life.


Distribution
In animals, based on total radioactivity, Cabergoline (and/or its metabolites) has shown extensive tissue distribution. Radioactivity in the pituitary exceeded that in plasma by >100-fold and was eliminated with a half-life of approximately 60 hours. This finding is consistent with the long-lasting prolactin-lowering effect of the drug. Whole body autoradiography studies in pregnant rats showed no fetal uptake but high levels in the uterine wall. Significant radioactivity (parent plus metabolites) detected in the milk of lactating rats suggests a potential for exposure to nursing infants. The drug is extensively distributed throughout the body. Cabergoline is moderately bound (40% to 42%) to human plasma proteins in a concentration-independent manner. Concomitant dosing of highly protein-bound drugs is unlikely to affect its disposition.


Metabolism
In both animals and humans, Cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond or the urea moiety. Cytochrome P-450 mediated metabolism appears to be minimal. Cabergoline does not cause enzyme induction and/or inhibition in the rat. Hydrolysis of the acylurea or urea moiety abolishes the prolactin-lowering effect of Cabergoline, and major metabolites identified thus far do not contribute to the therapeutic effect.


Excretion
After oral dosing of radioactive Cabergoline to five healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively. Less than 4% of the dose was excreted unchanged in the urine. Nonrenal and renal clearances for Cabergoline are about 3.2 L/min and 0.08 L/min, respectively. Urinary excretion in hyperprolactinemic patients was similar.


Special Populations

Renal Insufficiency
The pharmacokinetics of Cabergoline were not altered in 12 patients with moderate-to-severe renal insufficiency as assessed by creatinine clearance.


Hepatic Insufficiency
In 12 patients with mild-to-moderate hepatic dysfunction (Child-Pugh score ≤10), no effect on mean Cabergoline Cmax or area under the plasma concentration curve (AUC) was observed. However, patients with severe insufficiency (Child-Pugh score >10) show a substantial increase in the mean Cabergoline Cmax and AUC, and thus necessitate caution.


Elderly
Effect of age on the pharmacokinetics of Cabergoline has not been studied.


Food-Drug Interaction
In 12 healthy adult volunteers, food did not alter Cabergoline kinetics.


Pharmacodynamics
Dose response with inhibition of plasma prolactin, onset of maximal effect, and duration of effect has been documented following single Cabergoline doses to healthy volunteers (0.05 to 1.5 mg) and hyperprolactinemic patients (0.3 to 1 mg). In volunteers, prolactin inhibition was evident at doses >0.2 mg, while doses ≥0.5 mg caused maximal suppression in most subjects. Higher doses produce prolactin suppression in a greater proportion of subjects and with an earlier onset and longer duration of action. In 12 healthy volunteers, 0.5, 1, and 1.5 mg doses resulted in complete prolactin inhibition, with a maximum effect within 3 hours in 92% to 100% of subjects after the 1 and 1.5 mg doses compared with 50% of subjects after the 0.5 mg dose.

In hyperprolactinemic patients (N=51), the maximal prolactin decrease after a 0.6 mg single dose of Cabergoline was comparable to 2.5 mg bromocriptine; however, the duration of effect was markedly longer (14 days vs 24 hours). The time to maximal effect was shorter for bromocriptine than Cabergoline (6 hours vs 48 hours).

In 72 healthy volunteers, single or multiple doses (up to 2 mg) of Cabergoline resulted in selective inhibition of prolactin with no apparent effect on other anterior pituitary hormones (GH, FSH, LH, ACTH, and TSH) or cortisol.


Indications and Usage for Cabergoline
Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.


Contraindications
Cabergoline tablets are contraindicated in patients with uncontrolled hypertension or known hypersensitivity to ergot derivatives.


Warnings
Dopamine agonists in general should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia and eclampsia, unless the potential benefit is judged to outweigh the possible risk.


Precautions

General
Initial doses higher than 1.0 mg may produce orthostatic hypotension. Care should be exercised when administering Cabergoline with other medications known to lower blood pressure.


Postpartum Lactation Inhibition or Suppression
Cabergoline is not indicated for the inhibition or suppression of physiologic lactation. Use of bromocriptine, another dopamine agonist for this purpose, has been associated with cases of hypertension, stroke, and seizures.


Hepatic Impairment
Since Cabergoline is extensively metabolized by the liver, caution should be used, and careful monitoring exercised, when administering Cabergoline to patients with hepatic impairment.


Information for Patients
A patient should be instructed to notify her physician if she suspects she is pregnant, becomes pregnant, or intends to become pregnant during therapy. A pregnancy test should be done if there is any suspicion of pregnancy and continuation of treatment should be discussed with her physician.


Drug Interactions
Cabergoline should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.


Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity studies were conducted in mice and rats with Cabergoline given by gavage at doses up to 0.98 mg/kg/day and 0.32 mg/kg/day, respectively. These doses are 7 times and 4 times the maximum recommended human dose calculated on a body surface area basis using total mg/m2/week in rodents and mg/m2/week for a 50 kg human.

There was a slight increase in the incidence of cervical and uterine leiomyomas and uterine leiomyosarcomas in mice. In rats, there was a slight increase in malignant tumors of the cervix and uterus and interstitial cell adenomas. The occurrence of tumors in female rodents may be related to the prolonged suppression of prolactin secretion because prolactin is needed in rodents for the maintenance of the corpus luteum. In the absence of prolactin, the estrogen/progesterone ratio is increased, thereby increasing the risk for uterine tumors. In male rodents, the decrease in serum prolactin levels was associated with an increase in serum luteinizing hormone, which is thought to be a compensatory effect to maintain testicular steroid synthesis. Since these hormonal mechanisms are thought to be species-specific, the relevance of these tumors to humans is not known.

The mutagenic potential of Cabergoline was evaluated and found to be negative in a battery of in vitro tests. These tests included the bacterial mutation (Ames) test with Salmonella typhimurium, the gene mutation assay with Schizosaccharomyces pombe P1 and V79 Chinese hamster cells, DNA damage and repair in Saccharomyces cerevisiae D4, and chromosomal aberrations in human lymphocytes. Cabergoline was also negative in the bone marrow micronucleus test in the mouse.

In female rats, a daily dose of 0.003 mg/kg for 2 weeks prior to mating and throughout the mating period inhibited conception. This dose represents approximately 1/28 the maximum recommended human dose calculated on a body surface area basis using total mg/m2/week in rats and mg/m2/week for a 50 kg human.


Pregnancy

Teratogenic Effects: Category B
Reproduction studies have been performed with Cabergoline in mice, rats, and rabbits administered by gavage.

(Multiples of the maximum recommended human dose in this section are calculated on a body surface area basis using total mg/m2/week for animals and mg/m2/week for a 50 kg human.)

There were maternotoxic effects but no teratogenic effects in mice given Cabergoline at doses up to 8 mg/kg/day (approximately 55 times the maximum recommended human dose) during the period of organogenesis.

A dose of 0.012 mg/kg/day (approximately 1/7 the maximum recommended human dose) during the period of organogenesis in rats caused an increase in post-implantation embryofetal losses. These losses could be due to the prolactin inhibitory properties of Cabergoline in rats. At daily doses of 0.5 mg/kg/day (approximately 19 times the maximum recommended human dose) during the period of organogenesis in the rabbit, Cabergoline caused maternotoxicity characterized by a loss of body weight and decreased food consumption. Doses of 4 mg/kg/day (approximately 150 times the maximum recommended human dose) during the period of organogenesis in the rabbit caused an increased occurrence of various malformations. However, in another study in rabbits, no treatment-related malformations or embryofetotoxicity were observed at doses up to 8 mg/kg/day (approximately 300 times the maximum recommended human dose).

In rats, doses higher than 0.003 mg/kg/day (approximately 1/28 the maximum recommended human dose) from 6 days before parturition and throughout the lactation period inhibited growth and caused death of offspring due to decreased milk secretion.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.


Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Cabergoline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Use of Cabergoline for the inhibition or suppression of physiologic lactation is not recommended (see PRECAUTIONS section).

The prolactin-lowering action of Cabergoline suggests that it will interfere with lactation. Due to this interference with lactation, Cabergoline should not be given to women postpartum who are breastfeeding or who are planning to breastfeed.


Pediatric Use
Safety and effectiveness of Cabergoline in pediatric patients have not been established.


Geriatric Use
Clinical studies of Cabergoline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.


Adverse Reactions
The safety of Cabergoline tablets has been evaluated in more than 900 patients with hyperprolactinemic disorders. Most adverse events were mild or moderate in severity.

In a 4-week, double-blind, placebo-controlled study, treatment consisted of placebo or Cabergoline at fixed doses of 0.125, 0.5, 0.75, or 1.0 mg twice weekly. Doses were halved during the first week. Since a possible dose-related effect was observed for nausea only, the four Cabergoline treatment groups have been combined. The incidence of the most common adverse events during the placebo-controlled study is presented in the following table.

Incidence of Reported Adverse Events During the 4-Week, Double-Blind, Placebo-Controlled Trial Adverse Event* Cabergoline
(n=168)
0.125 to 1 mg two
times a week Placebo
(n=20)
Number (percent)
*
Reported at ≥1% for Cabergoline
Gastrointestinal
Nausea 45 (27) 4 (20)
Constipation 16 (10) 0
Abdominal pain 9 (5) 1 (5)
Dyspepsia 4 (2) 0
Vomiting 4 (2) 0
Central and Peripheral Nervous System
Headache 43 (26) 5 (25)
Dizziness 25 (15) 1 (5)
Paresthesia 2 (1) 0
Vertigo 2 (1) 0
Body As a Whole
Asthenia 15 (9) 2 (10)
Fatigue 12 (7) 0
Hot flashes 2 (1) 1 (5)
Psychiatric
Somnolence 9 (5) 1 (5)
Depression 5 (3) 1 (5)
Nervousness 4 (2) 0
Autonomic Nervous System
Postural hypotension 6 (4) 0
Reproductive – Female
Breast pain 2 (1) 0
Dysmenorrhea 2 (1) 0
Vision
Abnormal vision 2 (1) 0

In the 8-week, double-blind period of the comparative trial with bromocriptine, Cabergoline (at a dose of 0.5 mg twice weekly) was discontinued because of an adverse event in 4 of 221 patients (2%) while bromocriptine (at a dose of 2.5 mg two times a day) was discontinued in 14 of 231 patients (6%). The most common reasons for discontinuation from Cabergoline were headache, nausea and vomiting (3, 2 and 2 patients respectively); the most common reasons for discontinuation from bromocriptine were nausea, vomiting, headache, and dizziness or vertigo (10, 3, 3, and 3 patients respectively). The incidence of the most common adverse events during the double-blind portion of the comparative trial with bromocriptine is presented in the following table.

Incidence of Reported Adverse Events During the 8-Week, Double-Blind Period of the Comparative Trial With Bromocriptine Adverse Event* Cabergoline
(n=221) Bromocriptine
(n=231)
Number (percent)
*
Reported at ≥1% for Cabergoline
Gastrointestinal
Nausea 63 (29) 100 (43)
Constipation 15 (7) 21 (9)
Abdominal pain 12 (5) 19 (8)
Dyspepsia 11 (5) 16 (7)
Vomiting 9 (4) 16 (7)
Dry mouth 5 (2) 2 (1)
Diarrhea 4 (2) 7 (3)
Flatulence 4 (2) 3 (1)
Throat irritation 2 (1) 0
Toothache 2 (1) 0
Central and Peripheral Nervous System
Headache 58 (26) 62 (27)
Dizziness 38 (17) 42 (18)
Vertigo 9 (4) 10 (4)
Paresthesia 5 (2) 6 (3)
Body As a Whole
Asthenia 13 (6) 15 (6)
Fatigue 10 (5) 18 (8)
Syncope 3 (1) 3 (1)
Influenza-like symptoms 2 (1) 0
Malaise 2 (1) 0
Periorbital edema 2 (1) 2 (1)
Peripheral edema 2 (1) 1
Psychiatric
Depression 7 (3) 5 (2)
Somnolence 5 (2) 5 (2)
Anorexia 3 (1) 3 (1)
Anxiety 3 (1) 3 (1)
Insomnia 3 (1) 2 (1)
Impaired concentration 2 (1) 1
Nervousness 2 (1) 5 (2)
Cardiovascular
Hot flashes 6 (3) 3 (1)
Hypotension 3 (1) 4 (2)
Dependent edema 2 (1) 1
Palpitation 2 (1) 5 (2)
Reproductive – Female
Breast pain 5 (2) 8 (3)
Dysmenorrhea 2 (1) 1
Skin and Appendages
Acne 3 (1) 0
Pruritus 2 (1) 1
Musculoskeletal
Pain 4 (2) 6 (3)
Arthralgia 2 (1) 0
Respiratory
Rhinitis 2 (1) 9 (4)
Vision
Abnormal vision 2 (1) 2 (1)

Other adverse events that were reported at an incidence of <1.0% in the overall clinical studies follow.

Body As a Whole: facial edema, influenza-like symptoms, malaise
Cardiovascular System: hypotension, syncope, palpitations
Digestive System: dry mouth, flatulence, diarrhea, anorexia
Metabolic and Nutritional System: weight loss, weight gain
Nervous System: somnolence, nervousness, paresthesia, insomnia, anxiety
Respiratory System: nasal stuffiness, epistaxis
Skin and Appendages: acne, pruritus
Special Senses: abnormal vision
Urogenital System: dysmenorrhea, increased libido

The safety of Cabergoline has been evaluated in approximately 1,200 patients with Parkinson's disease in controlled and uncontrolled studies at dosages of up to 11.5 mg/day which greatly exceeds the maximum recommended dosage of Cabergoline for hyperprolactinemic disorders. In addition to the adverse events that occurred in the patients with hyperprolactinemic disorders, the most common adverse events in patients with Parkinson's disease were dyskinesia, hallucinations, confusion, and peripheral edema. Heart failure, pleural effusion, pulmonary fibrosis, and gastric or duodenal ulcer occurred rarely. One case of constrictive pericarditis has been reported.


Overdosage
Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.


Cabergoline Dosage and Administration
The recommended dosage of Cabergoline tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient's serum prolactin level.

Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered.

After a normal serum prolactin level has been maintained for 6 months, Cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with Cabergoline should be reinstituted. The durability of efficacy beyond 24 months of therapy with Cabergoline has not been established.


How is Cabergoline Supplied
Cabergoline tablets are white, scored, capsule-shaped tablets containing 0.5 mg Cabergoline. Each tablet is scored. The tablet has the letter G engraved on one side, the other side is engraved with the number 100.

Cabergoline is available as follows:

Bottles of 8 tablets NDC 59762-0100-1


STORAGE
Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].


Rx only

LAB-0304-3.0

http://www.drugs.com/pro/cabergoline.html



Merc.

[crabbypaddy]

Merc, that’s awesome thanks!

I will see what I can do to get my hands on some caber, otherwise I am sure I will have no choice but to start PCT and end this cycle. I like the effects of the AAS on my physique but I am not ready to park it in the garage!

[spywizard]

Just so you know.. t3 will increase your levels, but it will suppress your natural production of t3..

t4 will help to increase your natural levels of t3

[crabbypaddy]

Thanks Spywizard,
I researched t3 at steriod.com and it looks like I could regain my t3 levels after short (9 more weeks) suppression.

Do you think I should stay away from the t3 and wait until I can find the caber instead?

[Jeff1]

I had the same problem about 10 weeks in but didnt care finished the cycle and ran good PCT and Im back to normal now... With me its always been a part of the game.

[OnT]

Its all in your mind. The more you worry about it the more difficult it will be to get an erection. Keep working out and living your life, don't think about it and one day you'll wake up with a huge stiffy and bone your wife or girlfriend like there's no tomorrow. Trust me been there...

[bbminded]

just give it a few more weeks and the test will be kicked in all the way. then you should have a problem keeping it down. LOL get some aspire36

[pigrond]

dbols should have him up already always worked for me .

[Wavelover]

About cabergoline=Dostinex, read these :

It has at times been used as an adjunct to SSRI antidepressants as there is some evidence that it counteracts certain side effects of those drugs, such as reduced libido and anorgasmia. It also has been suggested online that it has a possible recreational use in reducing or eliminating the male refractory period. It is also used by bodybuilders to control gynecomastia caused by elevated prolactin levels caused by use of anabolic steroids such as Nandrolone.

[crabbypaddy]

I finished my d-bol last Monday and dropped the Tamoxifen, and things are working very well!
I want to thank you guys and gals for your advice it was a pretty scary time for me. I learned allot, I was under the impression that this was not normal. It was comforting to find out that it is normal for some and there are solutions.
Thanks again!

[RAWDEAL:]

could be estrogen related ditch the tamox for a while and see if that helps. I normally dont see a rise in libido on test e till about wks 4-6 so you may see a jump soon. also are you gyno prone cause if your not dont run the tamox till pct unless you see signs of gyno.

BUMP...i hit 3rd week..my cock swells like my bi's noww..what a pump..give it time Bro..